Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 3/20 | 0.58 |
| ▸ | CTSL | P07711 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482694 | 0.90 | CTSV (0.67) | CTSVCTSLKMT2AMEN1MAPT | |
| SCHEMBL6480305 | 0.89 | CTSV (0.65) | CTSVCTSLKMT2AMEN1MAPT | |
| SCHEMBL6474702 | 0.85 | CTSV (0.63) | CTSVCTSLKMT2AMEN1MAPT | |
| SCHEMBL6474969 | 0.85 | KMT2A (0.66) | CTSVCTSLKMT2AMEN1MAPT | |
| SCHEMBL6484456 | 0.84 | CTSV (0.78) | CTSVCTSLKMT2AMEN1MAPT | |
| SCHEMBL7331642 | 0.83 | CTSV (0.77) | CTSVCTSLKMT2AMEN1MAPT | |
| SCHEMBL6484226 | 0.83 | CTSV (0.73) | CTSVCTSLKMT2AMEN1MAPT | |
| SCHEMBL6482858 | 0.82 | MEN1 (0.70) | KMT2AMEN1AKR1C3AKR1C2BLM | |
| SCHEMBL6475459 | 0.81 | KMT2A (0.60) | CTSVCTSLKMT2AMEN1MAPT | |
| SCHEMBL6482234 | 0.81 | KMT2A (0.60) | CTSVCTSLKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972287-B1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | PFIZER INC. (US) | 2005-12-06 | — | — | US | claimed |
| EP-1225886-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2000076489-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
| US-6972287-B1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | PFIZER INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-6846890-B2 | Norbornene derivative and norbornene polymer obtained therefrom through ring opening polymerization | JSR CORPORATION (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20040242824-A1 | NORBORNENE DERIVATIVE AND NORBORNENE POLYMER OBTAINED THEREFROM THROUGH RING OPENING POLYMERIZATION | JSR CORPORATION (JP) | 2004-12-02 | — | — | US | disclosed |
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-11-04 | — | — | US | disclosed |
| EP-1435350-A1 | NORBORNENE DERIVATIVE AND NORBORNENE POLYMER OBTAINED THEREFROM THROUGH RING-OPENING POLYMERIZATION | JSR Corporation (JP) | 2004-07-07 | — | — | EP | disclosed |
| EP-1225886-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2000076489-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | APP, PSEN1, BACE1 | CTSV 2743/4885CTSL 3193/4885KMT2A 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.